Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi: 10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Wang G, Zhao D, Spring DJ, et al. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17–18):1105–1140. doi: 10.1101/gad.315739.118
   PubMed Web of Science ®Google Scholar
• Park H, Lee SW, Song G, et al. Diagnostic performance of%[-2] proPSA and prostate health index for prostate cancer: prospective, multi-institutional study. J Korean Med Sci. 2018;33(11): doi: 10.3346/jkms.2018.33.e94
   Web of Science ®Google Scholar
• White J, Shenoy BV, Tutrone RF, et al. Clinical utility of the prostate health index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis. 2018;21(1):78–84. doi: 10.1038/s41391-017-0008-7
   PubMed Web of Science ®Google Scholar
• Diamandis EP. New diagnostic applications and physiological functions of prostate specific antigen. Scand J Clin Lab Invest Suppl. 1995;221(sup221):105–112. doi: 10.3109/00365519509090573
   PubMedGoogle Scholar
• Klotz L. Overdiagnosis in urologic cancer: for World journal of Urology symposium on active surveillance in prostate and renal cancer. World J Urol. 2022;40(1):1–8. doi: 10.1007/s00345-020-03523-2
   PubMed Web of Science ®Google Scholar
• Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042
   PubMed Web of Science ®Google Scholar
• Loeb S, Gonzalez CM, Roehl KA, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol. 2006;175(3):902–906. doi: 10.1016/S0022-5347(05)00327-7
   PubMed Web of Science ®Google Scholar
• Liu D, Lehmann HP, Frick KD, et al. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol. 2012;187(4):1241–1246. doi: 10.1016/j.juro.2011.12.015
   PubMedGoogle Scholar
• Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50–58. doi: 10.1001/jama.2010.1923
   PubMed Web of Science ®Google Scholar
• Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the international society of geriatric oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116–136. doi: 10.1016/j.ejca.2019.04.031
   PubMed Web of Science ®Google Scholar
• Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol. 2012;30(2):143–148. doi: 10.1007/s00345-011-0801-1
   PubMed Web of Science ®Google Scholar
• Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66(3):489–499. doi: 10.1016/j.eururo.2014.01.003
   PubMed Web of Science ®Google Scholar
• Gulati R, Cheng HH, Lange PH, et al. Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev. 2017;26(2):222–227. doi: 10.1158/1055-9965.EPI-16-0434
   PubMed Web of Science ®Google Scholar
• Roobol MJ, Verbeek JFM, van der Kwast T, et al. Improving the rotterdam European randomized study of screening for prostate cancer risk calculator for Initial prostate biopsy by incorporating the 2014 international society of urological pathology gleason grading and cribriform growth. Eur Urol. 2017;72(1):45–51. doi: 10.1016/j.eururo.2017.01.033
   PubMed Web of Science ®Google Scholar
• Deniffel D, Healy GM, Dong X, et al. Avoiding unnecessary biopsy: MRI-based risk models versus a PI-RADS and PSA density strategy for clinically significant prostate cancer. Radiology. 2021;300(2):369–379. doi: 10.1148/radiol.2021204112
   PubMed Web of Science ®Google Scholar
• Eklund M, Jäderling F, Discacciati A, et al. MRI-Targeted or standard biopsy in prostate cancer screening. N Engl J Med. 2021;385(10):908–920. doi: 10.1056/NEJMoa2100852
   PubMed Web of Science ®Google Scholar
• Wagaskar VG, Sobotka S, Ratnani P, et al. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer. Cancer Rep (Hoboken). 2021;4(4):e1357. doi: 10.1002/cnr2.1357
   PubMedGoogle Scholar
• Hendriks RJ, van der Leest MMG, Israël B, et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer Prostatic Dis. 2021;24(4):1110–1119. doi: 10.1038/s41391-021-00367-8
   PubMed Web of Science ®Google Scholar
• Wagaskar VG, Levy M, Ratnani P, et al. Clinical utility of negative multiparametric magnetic resonance imaging in the diagnosis of prostate cancer and clinically significant prostate cancer. Eur Urol Open Sci. 2021;28:9–16. doi: 10.1016/j.euros.2021.03.008
   PubMedGoogle Scholar
• Bloom JB, Hale GR, Gold SA, et al. Predicting gleason group progression for men on prostate cancer active surveillance: role of a negative confirmatory magnetic resonance imaging-ultrasound fusion biopsy. J Urol. 2019;201(1):84–90. doi: 10.1016/j.juro.2018.07.051
   PubMed Web of Science ®Google Scholar
• Klotz L, Pond G, Loblaw A, et al. Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol. 2020;77(3):311–317. doi: 10.1016/j.eururo.2019.10.007
   PubMed Web of Science ®Google Scholar
• Amin A, Scheltema MJ, Shnier R, et al. The magnetic resonance imaging in active surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies. J Urol. 2020;203(5):910–917. doi: 10.1097/JU.0000000000000693
   PubMed Web of Science ®Google Scholar
• Gómez Gómez E, Puche Sanz I, Valero Rosa J, et al. Serum biomarkers for diagnosis and characterization of prostate cancer. Arch Esp Urol. 2022;75(2):156–164.
   PubMed Web of Science ®Google Scholar
• Barisiene M, Bakavicius A, Stanciute D, et al. Prostate health index and prostate health index density as diagnostic tools for improved prostate cancer detection. Biomed Res Int. 2020;2020:9872146. doi: 10.1155/2020/9872146
   PubMed Web of Science ®Google Scholar
• Tan LG, Tan YK, Tai BC, et al. Prospective validation of %p2PSA and the prostate health index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1. Asian J Androl. 2017;19(3):286–290. doi: 10.4103/1008-682X.168687
   PubMed Web of Science ®Google Scholar
• Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi: 10.1038/s41572-020-00243-0
   PubMed Web of Science ®Google Scholar
• Ferro M, De Cobelli O, Lucarelli G, et al. Beyond PSA: the role of prostate health index (phi). IJMS. 2020;21(4):1184. doi: 10.3390/ijms21041184
   Google Scholar
• Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign Prostatic disease: a prospective multicenter clinical trial. J Urol. 1999;161(1):353–354. doi: 10.1016/S0022-5347(01)62151-7
   Google Scholar
• Huang Y, Li Z-Z, Huang Y-L, et al. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: a meta-analysis. Medicine. 2018;97(13):e0249. doi: 10.1097/MD.0000000000010249
   PubMed Web of Science ®Google Scholar
• Roobol MJ, van Vugt HA, Loeb S, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61(3):577–583. doi: 10.1016/j.eururo.2011.11.012
   PubMed Web of Science ®Google Scholar
• Ankerst DP, Hoefler J, Bock S, et al. Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83(6):1362–1368. doi: 10.1016/j.urology.2014.02.035
   PubMed Web of Science ®Google Scholar
• Louie KS, Seigneurin A, Cathcart P, et al. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26(5):848–864. doi: 10.1093/annonc/mdu525
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004;171(6 Part 1):2239–2244. doi: 10.1097/01.ju.0000127737.94221.3e
   PubMed Web of Science ®Google Scholar
• Ferro M, Crocetto F, Bruzzese D, et al. Prostate health index and multiparametric MRI: partners in crime fighting overdiagnosis and overtreatment in prostate cancer. Cancers. 2021;13(18):4723. doi: 10.3390/cancers13184723
   PubMed Web of Science ®Google Scholar
• Carroll PR, Parsons JK, Andriole G, et al. NCCN guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw. 2016;14(5):509–519. doi: 10.6004/jnccn.2016.0060
   PubMed Web of Science ®Google Scholar
• Stattin P, Vickers AJ, Sjoberg DD, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case–control study. Eur Urol. 2015;68(2):207–213. doi: 10.1016/j.eururo.2015.01.009
   PubMed Web of Science ®Google Scholar
• Grönberg H, Adolfsson J, Aly M, et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16(16):1667–1676. doi: 10.1016/S1470-2045(15)00361-7
   PubMed Web of Science ®Google Scholar
• Ström P, Nordström T, Aly M, et al. The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential. Eur Urol. 2018;74(2):204–210. doi: 10.1016/j.eururo.2017.12.028
   PubMed Web of Science ®Google Scholar
• Grönberg H, Eklund M, Picker W, et al. Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging. Eur Urol. 2018;74(6):722–728. doi: 10.1016/j.eururo.2018.06.022
   PubMed Web of Science ®Google Scholar
• Terracciano D, La Civita E, Athanasiou A, et al. New strategy for the identification of prostate cancer: the combination of Proclarix and the prostate health index. Prostate. 2022;82(15):1469–1476. doi: 10.1002/pros.24422
   PubMed Web of Science ®Google Scholar
• Klocker H, Golding B, Weber S, et al. Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. BJUI Compass. 2020;1(1):15–20. doi: 10.1002/bco2.8
   PubMedGoogle Scholar
• Fujita K, Nonomura N. Urinary biomarkers of prostate cancer. Int J Urol. 2018;25(9):770–779. doi: 10.1111/iju.13734
   PubMed Web of Science ®Google Scholar
• Martignano F, Rossi L, Maugeri A, et al. Urinary RNA-based biomarkers for prostate cancer detection. Clin Chim Acta. 2017;473:96–105. doi: 10.1016/j.cca.2017.08.009
   PubMed Web of Science ®Google Scholar
• Salciccia S, Capriotti AL, Laganà A, et al. Biomarkers in prostate cancer diagnosis: from Current knowledge to the role of metabolomics and exosomes. Int J Mol Sci. 2021;22(9):4367. doi: 10.3390/ijms22094367
   PubMed Web of Science ®Google Scholar
• Cerrato A, Bedia C, Capriotti AL, et al. Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine. Anal Chim Acta. 2021;1158:338381. doi: 10.1016/j.aca.2021.338381
   PubMed Web of Science ®Google Scholar
• Logozzi M, Mizzoni D, Di Raimo R, et al. Plasmatic exosome number and size distinguish prostate cancer patients from healthy individuals: a prospective clinical study. Front Oncol. 2021;11:727317. doi: 10.3389/fonc.2021.727317
   PubMed Web of Science ®Google Scholar
• Sciarra A, Di Lascio G, Del Giudice F, et al. Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review. Curr Urol. 2021;15(1):22–32. doi: 10.1097/CU9.0000000000000012
   PubMedGoogle Scholar
• Sciarra A, Salciccia S, Maggi M, et al. Elective procedures for prostate cancer in the time of covid-19: a multidisciplinary team experience. Prostate Cancer Prostatic Dis. 2020;23(3):407–409. doi: 10.1038/s41391-020-0240-4
   PubMed Web of Science ®Google Scholar
• Busetto GM, Del Giudice F, D’Agostino D, et al. Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: a critical review of the literature. Arch Ital Urol Androl. 2020;91(4):205–210. doi: 10.4081/aiua.2019.4.205
   PubMedGoogle Scholar
• Crawford ED, Rove KO, Trabulsi EJ, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012;188(5):1726–1731. doi: 10.1016/j.juro.2012.07.023
   PubMed Web of Science ®Google Scholar
• Wei JT, Feng Z, Partin AW, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014;32(36):4066–4072. doi: 10.1200/JCO.2013.52.8505
   PubMed Web of Science ®Google Scholar
• Cui Y, Cao W, Li Q, et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6(1):25776. doi: 10.1038/srep25776
   PubMedGoogle Scholar
• Visser WCH, de Jong H, Melchers WJG, et al. Commercialized blood-, urinary- and tissue-based biomarker tests for prostate cancer diagnosis and prognosis. Cancers (Basel). 2020;12(12):3790. doi: 10.3390/cancers12123790
   PubMed Web of Science ®Google Scholar
• Auprich M, Chun F-H, Ward JF, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011;59(1):96–105. doi: 10.1016/j.eururo.2010.10.024
   PubMed Web of Science ®Google Scholar
• Hessels D, van Gils MPMQ, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010;70(1):10–16. doi: 10.1002/pros.21032
   PubMed Web of Science ®Google Scholar
• Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69(3):532–535. doi: 10.1016/j.urology.2006.12.014
   PubMed Web of Science ®Google Scholar
• Gittelman MC, Hertzman B, Bailen J, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013;190(1):64–69. doi: 10.1016/j.juro.2013.02.018
   PubMed Web of Science ®Google Scholar
• Sanda MG, Feng Z, Howard DH, et al. Association between combined TMPRSS2: ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. JAMA Oncol. 2017;3(8):1085–1093. doi: 10.1001/jamaoncol.2017.0177
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2: ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 2016;70(1):45–53. doi: 10.1016/j.eururo.2015.04.039
   PubMed Web of Science ®Google Scholar
• Feibus AH, Sartor O, Moparty K, et al. Clinical use of PCA3 and TMPRSS2: ERG urinary biomarkers in African-American men undergoing prostate biopsy. J Urol. 2016;196(4):1053–1060. doi: 10.1016/j.juro.2016.04.075
   PubMed Web of Science ®Google Scholar
• Leyten GHJM, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534–542. doi: 10.1016/j.eururo.2012.11.014
   PubMed Web of Science ®Google Scholar
• McKiernan J, Donovan MJ, O’Neill V, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at Initial biopsy. JAMA Oncol. 2016;2(7):882–889. doi: 10.1001/jamaoncol.2016.0097
   PubMed Web of Science ®Google Scholar
• Donovan MJ, Noerholm M, Bentink S, et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 2015;18(4):370–375. doi: 10.1038/pcan.2015.40
   PubMed Web of Science ®Google Scholar
• de la Calle CM, Fasulo V, Cowan JE, et al. Clinical utility of 4Kscore®, ExosomeDx™ and magnetic resonance imaging for the early detection of high grade prostate cancer. J Urol. 2021;205(2):452–460. doi: 10.1097/JU.0000000000001361
   PubMedGoogle Scholar
• Frantzi M, Heidegger I, Roesch MC, et al. Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer. World J Urol. 2022;40(9):2195–2203. doi: 10.1007/s00345-022-04077-1
   PubMed Web of Science ®Google Scholar
• Frantzi M, Gomez Gomez E, Blanca Pedregosa A, et al. CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. Br J Cancer. 2019;120(12):1120–1128. doi: 10.1038/s41416-019-0472-z
   PubMed Web of Science ®Google Scholar
• Mottet N, Van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.Eur Urol. 2021;79:243–262.
   PubMed Web of Science ®Google Scholar
• Falagario UG, Sanguedolce F, Dovey Z, et al. Prostate cancer biomarkers: a practical review based on different clinical scenarios. Crit Rev Clin Lab Sci. 2022;59(5):297–308. doi: 10.1080/10408363.2022.2033161
   PubMed Web of Science ®Google Scholar
• Leyten GHJM, Hessels D, Smit FP, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res. 2015;21(13):3061–3070. doi: 10.1158/1078-0432.CCR-14-3334
   PubMed Web of Science ®Google Scholar
• Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker–based risk score. Eur Urol. 2016;70(5):740–748. doi: 10.1016/j.eururo.2016.04.012
   PubMed Web of Science ®Google Scholar
• Visser WCH, de Jong H, Steyaert S, et al. Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):583–589. doi: 10.1038/s41391-022-00562-1
   PubMed Web of Science ®Google Scholar
• Haese A, Trooskens G, Steyaert S, et al. Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer before Initial prostate biopsy. J Urol. 2019;202(2):256–263. doi: 10.1097/JU.0000000000000293
   PubMed Web of Science ®Google Scholar
• Fiorella D, Marenco JL, Mascarós JM, et al. Papel de PCA3 y SelectMDx en la optimización de la vigilancia activa en el cáncer de próstata. Actas Urológicas Españolas. 2021;45(6):439–446. doi: 10.1016/j.acuro.2020.10.010
   PubMedGoogle Scholar
• Pepe P, Dibenedetto G, Pepe L, et al. Multiparametric MRI versus SelectMDx accuracy in the diagnosis of clinically significant PCa in men enrolled in active surveillance. In Vivo. 2020;34(1):393–396. doi: 10.21873/invivo.11786
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Omer A, Harriss E, et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis. Eur Urol. 2020;78(3):402–414. doi: 10.1016/j.eururo.2020.03.048
   PubMed Web of Science ®Google Scholar
• Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822. doi: 10.1016/S0140-6736(16)32401-1
   PubMed Web of Science ®Google Scholar
• Maggi M, Del Giudice F, Falagario UG, et al. SelectMDx and multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy: a prospective assessment in a multi-institutional study. Cancers (Basel). 2021;13(9):2047. doi: 10.3390/cancers13092047
   PubMed Web of Science ®Google Scholar
• Hendriks RJ, van der Leest MMG, Dijkstra S, et al. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. Prostate. 2017;77(14):1401–1407. doi: 10.1002/pros.23401
   PubMed Web of Science ®Google Scholar
• Roumiguié M, Ploussard G, Nogueira L, et al. Independent evaluation of the respective predictive values for high-grade prostate cancer of clinical information and RNA biomarkers after upfront MRI and image-guided biopsies. Cancers (Basel). 2020;12(2):285. doi: 10.3390/cancers12020285
   PubMed Web of Science ®Google Scholar
• Busetto GM, Del Giudice F, Maggi M, et al. Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy. World J Urol. 2021;39(6):1869–1877. doi: 10.1007/s00345-020-03359-w
   PubMed Web of Science ®Google Scholar
• Rahnama’i MS, Bach C, Schulze-Hagen M, et al. Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx? Cancer Rep (Hoboken). 2021;4(6):e1396. doi: 10.1002/cnr2.1396
   PubMedGoogle Scholar
• Lendínez-Cano G, Ojeda-Claro AV, Gómez-Gómez E, et al. Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test. Prostate. 2021;81(12):857–865. doi: 10.1002/pros.24182
   PubMed Web of Science ®Google Scholar
• Wagaskar VG, Levy M, Ratnani P, et al. A SelectMDx/magnetic resonance imaging-based nomogram to diagnose prostate cancer. Cancer Rep (Hoboken). 2023;6(1):e1668. doi: 10.1002/cnr2.1668
   PubMedGoogle Scholar
• Katzendorn O, von Klot CAJ, Mahjoub S, et al. Combination of PI-RADS score and mRNA urine test—A novel scoring system for improved detection of prostate cancer. PLoS One. 2022;17(8):e0271981. doi: 10.1371/journal.pone.0271981
   PubMed Web of Science ®Google Scholar
• Borghesi M, Ahmed H, Nam R, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71(3):353–365. doi: 10.1016/j.eururo.2016.08.004
   PubMed Web of Science ®Google Scholar
• Garcia-Marques F, Liu S, Totten SM, et al. Protein signatures to distinguish aggressive from indolent prostate cancer. Prostate. 2022;82(5):605–616. doi: 10.1002/pros.24307
   PubMed Web of Science ®Google Scholar
• Kohaar I, Chen Y, Banerjee S, et al. A urine exosome gene expression panel distinguishes between indolent and aggressive prostate Cancers at biopsy. J Urol. 2021;205(2):420–425. doi: 10.1097/JU.0000000000001374
   PubMed Web of Science ®Google Scholar
• Tătaru OS, Vartolomei MD, Rassweiler JJ, et al. Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management—Current Trends and Future Perspectives. Diagnostics. 2021;11(2):354. doi: 10.3390/diagnostics11020354
   Web of Science ®Google Scholar
• Alarcón-Zendejas AP, Scavuzzo A, Jiménez-Ríos MA, et al. The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches. Prostate Cancer Prostatic Dis. 2022;25(3):431–443. doi: 10.1038/s41391-022-00537-2
   PubMed Web of Science ®Google Scholar
• Spratt DE, Zhang J, Santiago-Jiménez M, et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J Clin Oncol. 2018;36(6):581–590. doi: 10.1200/JCO.2017.74.2940
   PubMed Web of Science ®Google Scholar
• Wyatt AW, Annala M, Aggarwal R, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2017;109(12):djx118. doi: 10.1093/jnci/djx118
   PubMedGoogle Scholar
• Crocetto F, Russo G, Di Zazzo E, et al. Liquid biopsy in prostate cancer management—current challenges and future perspectives. Cancers (Basel). 2022;14(13):3272. doi: 10.3390/cancers14133272
   PubMed Web of Science ®Google Scholar
• Liberini V, Laudicella R, Balma M, et al. Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics. Eur Radiol Exp. 2022;6(1):27. doi: 10.1186/s41747-022-00282-0
   PubMedGoogle Scholar
• Ferro M, de Cobelli O, Musi G, et al. Radiomics in prostate cancer: an up-to-date review. Ther Adv Urol. 2022;14:17562872221109020. doi: 10.1177/17562872221109020
   Web of Science ®Google Scholar
• Thenault R, Gasmi A, Khene Z-E, et al. Radiogenomics in prostate cancer evaluation. Curr Opin Urol. 2021;31(4):424–429. doi: 10.1097/MOU.0000000000000902
   PubMed Web of Science ®Google Scholar
• Ferro M, de Cobelli O, Vartolomei MD, et al. Prostate Cancer Radiogenomics—From Imaging to Molecular Characterization. Int J Mol Sci. 2021;22(18):9971. doi: 10.3390/ijms22189971
   PubMed Web of Science ®Google Scholar
• Casanova-Salas I, Athie A, Boutros PC, et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer. Eur Urol. 2021;79(6):762–771. doi: 10.1016/j.eururo.2020.12.037
   PubMed Web of Science ®Google Scholar